Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Standard BioTools Inc (NASDAQ: LAB) closed at $2.44 up 3.39% from its previous closing price of $2.36. In other words, the price has increased by $3.39 from its previous closing price. On the day, 3.64 million shares were traded. LAB stock price reached its highest trading level at $2.45 during the session, while it also had its lowest trading level at $2.31.
Ratios:
For a deeper understanding of Standard BioTools Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.26 and its Current Ratio is at 1.45. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.21.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on April 16, 2024, initiated with a Buy rating and assigned the stock a target price of $3.50.
On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.
On July 12, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $4.KeyBanc Capital Markets initiated its Overweight rating on July 12, 2023, with a $4 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 05 ’24 when Casdin Partners Master Fund, L bought 1,403 shares for $2.62 per share. The transaction valued at 3,669 led to the insider holds 11,497,928 shares of the business.
Casdin Partners Master Fund, L bought 250,000 shares of LAB for $642,500 on Mar 04 ’24. The Director now owns 11,496,525 shares after completing the transaction at $2.57 per share. On May 19 ’23, another insider, Casdin Eli, who serves as the Director of the company, bought 800,000 shares for $2.29 each. As a result, the insider paid 1,835,920 and bolstered with 1,200,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 933204864 and an Enterprise Value of 270227872. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.79. Its current Enterprise Value per Revenue stands at 2.541 whereas that against EBITDA is -4.576.
Stock Price History:
Over the past 52 weeks, LAB has reached a high of $3.16, while it has fallen to a 52-week low of $1.46. The 50-Day Moving Average of the stock is -6.25%, while the 200-Day Moving Average is calculated to be 0.65%.
Shares Statistics:
For the past three months, LAB has traded an average of 2.11M shares per day and 2868680 over the past ten days. A total of 383.05M shares are outstanding, with a floating share count of 369.48M. Insiders hold about 3.54% of the company’s shares, while institutions hold 54.22% stake in the company. Shares short for LAB as of 1713139200 were 11277340 with a Short Ratio of 5.34, compared to 1710460800 on 9261427. Therefore, it implies a Short% of Shares Outstanding of 11277340 and a Short% of Float of 3.09.
